Alex Chehrazi-Raffle, MD, compared the characteristics of patients with bladder cancer who received nivolumab vs those who received chemotherapy after surgery. This study was a real-world outcomes study that was done in partnership with Cardinal Health and Bristol Myers Squibb. We are hoping to incorporate more of an outcomes analysis looking at events such as progression and depth to see how this fared.